These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 31892489)

  • 1. Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine.
    Modi ND; Sorich MJ; Rowland A; McKinnon RA; Koczwara B; Wiese MD; Hopkins AM
    Clin Breast Cancer; 2020 Apr; 20(2):e220-e228. PubMed ID: 31892489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
    Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
    Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
    Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
    Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
    J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
    N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
    Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
    Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
    Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
    Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
    Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis.
    Zhang J; Li J; Zhu C; Song Y; Xia F; Ma X
    Drug Des Devel Ther; 2017; 11():3235-3244. PubMed ID: 29180848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
    Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
    Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.
    Tang E; Rowland A; McKinnon RA; Sorich MJ; Hopkins AM
    Breast Cancer Res Treat; 2019 Nov; 178(2):473-477. PubMed ID: 31399933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
    Cortés J; Diéras V; Lorenzen S; Montemurro F; Riera-Knorrenschild J; Thuss-Patience P; Allegrini G; De Laurentiis M; Lohrisch C; Oravcová E; Perez-Garcia JM; Ricci F; Sakaeva D; Serpanchy R; Šufliarský J; Vidal M; Irahara N; Wohlfarth C; Aout M; Gelmon K
    JAMA Oncol; 2020 Aug; 6(8):1203-1209. PubMed ID: 32584367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
    Kashiwaba M; Ito Y; Takao S; Doihara H; Rai Y; Kanatani K; Takashima S; Masuda N
    Jpn J Clin Oncol; 2016 May; 46(5):407-14. PubMed ID: 26917603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
    Noda-Narita S; Shimomura A; Kawachi A; Sumiyoshi-Okuma H; Sudo K; Shimoi T; Noguchi E; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    Breast Cancer; 2019 Jul; 26(4):492-498. PubMed ID: 30737616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
    Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.